Interactions between outcomes and tumor response to preoperative cisplatin-sensitized radiotherapy in advanced head and neck cancer

American Journal of Surgery

Volumn 174, Issue 5, 1997, Pages 527-531

  Goodman, Martin D ^a   Tarnoff, Michael ^a   Kain, Michael ^a   Slotman, Gus J ^a   Cassir, Jorge ^b   Meltzer, Jeffrey ^b   Dalzell, James ^b   Nazha, Nairn ^b   Sykes, David ^b   Childs, Julianna ^b   Poet, Albert ^b   Ruiz, Victor ^b   Horowitz, Carolyn ^b   Harvey, Alexis ^b   Rothman, Harvey ^b   Fanelle, Joseph ^b   Robertello, William ^b   Ferrari, Arthur ^b   Blom, David ^b   Sudhindra, Rama ^b   Noble, Edward ^b   Porter, Bradford ^b   Goldberg, Kenneth ^b   Lustig, Robert ^b   Hageboutros, Alex ^b   Matise, Joseph ^b   more..

^a Department of Anesthesiology   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; DISEASE COURSE; FEMALE; HEAD AND NECK CANCER; HISTOPATHOLOGY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; PRIORITY JOURNAL; RADIOSENSITIZATION; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; CISPLATIN; COMBINED MODALITY THERAPY; FEMALE; FOLLOW-UP STUDIES; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; RADIATION-SENSITIZING AGENTS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME;

EID: 0030712887     PISSN: 00029610     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9610(97)00151-7     Document Type: Article

References (36)

1. Million R, Cassissi N, Clark J. Cancer of the head and neck. In: DeVita VT, Hellman S, Rosenberg SA, eds. Principles and Practice of Oncology. Philadelphia: Lippincott; 1989:488-580.
2. Tannock IF, Browman G. Lack of evidence for a role of chemotherapy in the routine management of locally advanced head and neck cancer. J Clin Oncol. 1986;4(7):1121-1126.
3. Rosenthal DI, Carbone DP. Taxol plus radiation for head and neck cancer. J Infusional Chemother. 1995;5(2):46-54.
4. Lefebrvre JL, Chevalier D, Luboinski B, et al. Larynx preservation in pyriform sinus cancer: preliminary results of a European Organization for Research and Treatment of Cancer phase III trial. J Nat Cancer Inst. 1996;88(13):890-899.
5. Forastere AA. Another look at induction chemotherapy for organ preservation in patients with head and neck cancer. J Nat Cancer Inst. 1996;88(13):855-856.
6. Adelstein DJ, Saxton JP, Van Kirk MA, et al. Continuous course radiation therapy and concurrent combination chemotherapy for squmuous cell head and neck cancer. Am J Clin Oncol. 1994;17:369-373.
7. Magno L, Terraneo F, Bertoni F, et al. Double-blind randomized study of lonidamine and radiotherapy in head and neck cancer. Int J Radiat Oncol Biol Phys. 1994;29:45-55.
8. Liggett W, Forastiere AA. Chemotherapy advances in head and neck oncology. Semin Surg Oncol. 1995;11:265-271.
9. Wheeler R, Spencer S. Cisplatin plus radiation therapy. J Infusional Chemother. 1995;5(2):61-66.
10. Stupp R, Yokes EE. 5-Fluorouracil plus radiation for head and neck cancer. J Infusional Chemother. 1995;5(2):55-60.
11. Slotrnan GJ, Cummings FJ, Glicksman AR, et al. Preoperative simultaneously administered cis-platinum plus radiation therapy for advanced squamous cell carcinoma of the head and neck. Head Neck Surg. 1986;8:159-164.
12. Slotman GJ, Doolittle CH, Ghcksman AS. Preoperattve combined chemotherapy and radiation therapy plus radical surgery in advanced head and neck cancer. Cancer. 1992:69:2736-2743.
13. Glicksman AS, Slotman GJ, Doolittle CH, et al. Concurrent cis-platinum and radiation with or without surgery for advanced head and neck cancer. Int J Radiat Oncol Biol Phys. 1994:30:1043-1050.
14. Wanebo HJ, Glicksman AS, Landman C, et al. Preoperative cisplatin and accelerated hyperfractionated radiation induces high tumor response and control rates in patients with advanced head and neck cancer. Am J Surg. 1995;170:512-516.
15. Forastiere AA. Overview of platinum chemotherapy in head and neck cancer. Semin Oncol. 1994;21(suppl):12:20-27.
16. Chougule PB, Suk S, Chu QD, et al. Cisplatin as a radiation sensitizer in the treatment of advanced head and neck cancers: results of a phase II study. Cancer. 1994:74:1927-1932.
17. Robbins KT, Vicario D, Seagren S, et al. A targeted supra dose cisplatin chemoradiation protocol for advanced head and neck cancer. Am J Surg. 1994;168:419-422.
18. Adelstein DJ, Sharan VM, Damm C, et al. Concurrent radiation therapy, 5-fluorouracil and cisplatin for stage III and IV nodenegative, squamous cell head and neck cancer. Results and surgical implications. Cancer. 1992;70:2685-2690.
19. Fonseca E, Cruz JJ, Gomez A, et al. Neoadjuvant chemotherapy with cisplatin and 5-fluorouracil, both in continuous 96-hour infusion, in the treatment of locally advanced head and neck cancer. Am J Clin Oncol. 1994;17:6-9.
20. Van den Bogaert W, Schueren E, Horiot JC, et al. The EORTC randomized trial on three fractions per day and misonidazole in advanced head and neck cancer: long term results and side effects. Radiother Oncol. 1995;35:91-99.
21. Taylor SG IV, Murphy AK, Vannetzel JM, et al. Randomized comparison of neoadjuvant cisplatin and fluorouracil infusion followed by radiation versus concomitant treatment in advanced head and neck cancer. Am J Clin Oncol. 1994:12:385-395.
22. Fu KK, Cooper JS, Marcial VA, et al. Evolution of the Radiation Therapy Oncology Group Clinical Trials for head and neck cancer. Int J Radiat Oncol Biol Phys. 1996;35:425-438.
23. Jones AS, Roland NJ, Field JK, Phillips DE. The level of cervical lymph node metastases: their prognostic relevance and relationship with head and neck squamous carcinoma primary sites. Clin Otolaryngol. 1994; 19:63-69.
24. Mamelle G, Pampurik J, Luboinski B, et al. Lymph node prognostic factors in head and neck squamous cell carcinomas. Am J Surg. 1994;168:494-498.
25. Shingaki S, Suzuki I, Kobayashi T, Nakajima T. Predicting factors for distant metastases in head and neck carcinomas: an analysis of 103 patients with locoregional control. J Oral Maxillofac Surg. 1996;54:853-857.
26. Gleich LL, Srivasatava L, Gluckman JL. Plasma platelet-derived growth factor: preliminary study of a potential marker in head and neck cancer. Arm Otol Rhinol Laryngol. 1996;105:710-712.
27. Thomas GR, Tubb EE, Sessions RB, Cullen KJ. Growth factor mRNA expression in human head and neck malignant tumors. Arch Otolaryngol Head Neck Surg. 1993;119:1247-1252.
28. McManus LM, Ostrom KK, Lear C, et al. Radiation-induced increased platelet-activating factor activity in mixed saliva. Lab Invest. 1993;68:118-124.
29. Zeimet AG, Marth C, Muller-Holzner E, et al. Significance of thrombocytosis in patients with epithelial ovarian cancer. Am J Obstet Gynecol. 1994:170:549-554.
30. Pedersen LM, Milman N. Prognostic significance of thrombocycosis in patients with primary lung cancer. Eur Respir J. 1996;9:1826-1830.
31. Rodriguez GC, Clarke-Peterson DL, Soper JT, et al. The negative prognostic implications of thrombocytosis in women with stage IB cervical cancer. Obstet Gynecol 1994;83:445-448.
32. 2 and prostacyclin concentration in squamous cell carcinoma of the head and neck. J Surg Oncol. 1998;38:33-37.
33. Thompson AC, Bradley PJ, Griffin NR. Tumor associated tissue eosinophilia and long term prognosis for carcinoma of the larynx. Am J Surg. 1994;168:469-471.
34. Fontana X, Dassonville O, Neri J, et al. Sedimentation rate and serum thymidine kinase activity: prognostic factors in squamous cell head and neck cancer. Head Neck Surg. 1993;15:425-432.
35. Ensley JF. The clinical application of DNA content and kinetic parameters in the treatment of patients with squamous cell carcinoma of the head and neck. Cancer Metastasis Rev. 1996;15:133-141.
36. Bradford CR, Zhu S, Wolf GT, et al. Overexpression of p53 predicts organ preservation using induction chemotherapy and radiation in patients with advanced laryngeal cancer. Otolaryngol Head Neck Surg. 1995;113:408-412.